// App-Quantinova.ai

TPS11071 : A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.

Researchers

Presenter

  • Mark Agulnik

Principal Investigators

  • Nizar M. Tannir

  • Joseph Gerald Pressey

  • Mrinal M. Gounder

  • Gregory Michael Cote

  • Maria Roche

  • Susan Doleman

  • Stephen J Blakemore

  • Alicia Clawson

  • Scott Daigle

  • Jeanie Tang

  • Peter T.C. Ho

  • George D. Demetri

Medical Centers

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Massachusetts General Hospital, Boston, MA

  • Epizyme, Cambridge, MA

  • Epizyme, Inc., Cambridge, MA.

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • United States

Companies

  • Epizyme, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal medullary carcinoma

  • Epithelioid sarcoma

  • Synovial sarcoma

  • Rhabdoid predisposition syndrome

  • Solid malignancies

  • Sarcoma

Biomarkers

  • Enhancer of zeste homolog 2

  • SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4

Drug/Treatment

  • Tazemetostat

  • EZH2

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT02601950

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved